Dr. J S. Magee, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (1976)
- Years since graduation
- 50
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 512
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1976Medical school: Perelman School of Med at the University of Pennsylvania
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME30740 -
Internal Medicine Physician
FL license ME30740 -
Specialist
FL license ME30740
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- Southeast Georgia Health System -- Camden Campus Saint Marys, GA
- Ed Fraser Memorial Hospital Macclenny, FL
Medical groups
- Northeast Florida Endocrine and Diabetes Associates PA (80 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 512
- Services billed
- 2,077
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,099 | 503 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 212 | 85 |
| Established patient office or other outpatient visit, 20-29 minutes | 86 | 62 |
| Ultrasound scan of head and neck soft tissue | 56 | 55 |
| New patient office or other outpatient visit, 45-59 minutes | 14 | 14 |
| Dxa bone density measurement of hip, pelvis, spine | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Jacksonville, FL | 539 |
| Jardiance (empagliflozin) Other prescribers in Jacksonville, FL | 284 |
| Ozempic (semaglutide) Other prescribers in Jacksonville, FL | 276 |
| Metformin Hcl Other prescribers in Jacksonville, FL | 268 |
| Synthroid (levothyroxine sodium) Other prescribers in Jacksonville, FL | 266 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Jacksonville, FL | 263 |
| Mounjaro (tirzepatide) Other prescribers in Jacksonville, FL | 215 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Jacksonville, FL | 198 |
| Rosuvastatin Calcium Other prescribers in Jacksonville, FL | 185 |
| Glimepiride Other prescribers in Jacksonville, FL | 171 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 75 payments worth $1,504 in total to this clinician.
| Medtronic, Inc. | $291 |
|---|---|
| Abbott Laboratories | $285 |
| Insulet Corporation | $148 |
| Corcept Therapeutics | $118 |
| Novo Nordisk Inc | $109 |
| Madrigal Pharmaceuticals | $102 |
| Lilly USA, LLC | $66.56 |
| Ascendis Pharma Endocrinology Inc | $63.51 |
| Food and Beverage | $1,504 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $592,074 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Eli Lilly and Company · Completed · NCT05872620 - The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Eli Lilly and Company · Active, not recruiting · NCT06383390 - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433 - A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients
Novartis Pharmaceuticals Corporation - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - Study name not reported
Novo Nordisk As
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.